All News

#ClinicalPearl Update on @eular #rheumatoid #arthritis guidelines. Reassuringly not much of an update. Very reasonable discussion of #JAKi safety. @RheumNow Day 1 of #EULAR202 T2T, shared decision making, limit #glucocorticoids to shortest time. Change MOA or not, after failure.

Janet Pope Janetbirdope ( View Tweet)

#POS0190 #EULAR2022 Disappointing news. Despite +ve Phase 2 RCT, Results from Phase 3 RCTs of Baricitinib in #lupus is inconclusive 💠SRI4 was met in BRAVE1 but not BRAVE2 despite identical study 💠BILAG MSK & Skin improved in BRAVE1 only BICLA wasn’t reported @RheumNow https://t.co/IfJRYEwFY8
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Combined nordic registers study: 🧠 demyelinating and inflammatory neuropathies in 50000+ patients starting TNFi 📍DML SpA > RA 📍INP SpA = RA 📍ETA = Other anti TNFi But no csDMARDs control group OP0060 #EULAR2022 @RheumNow https://t.co/LYqUW22rMg
Aurelie Najm AurelieRheumo ( View Tweet)
#Bestinclass #EULAR2022 #PsA @RheumNow #OP0027 #CVE #MACE with #Tofacitinib in #psoriatic #arthritis and #PsO with median 3 to 4 yrs Rx. 40% metabolic syndrome which is high. There was no comparison. As expected hose with ⬆️MACE risks had more outcomes. https://t.co/sTjFHsUxzi
Janet Pope Janetbirdope ( View Tweet)
The amazing @SuAnnYeoh1 oral presentation showing terminally differentiated T effector memory re-expressing CD45RA are associated persistent disease activity in TNF non-responders (but not other bDMARDs) ?role in driving disease @RheumNow #EULAR2022 OP0011 https://t.co/OFradjuGvo https://t.co/flpFmcvixO

Links:

Richard Conway RichardPAConway ( View Tweet)
Dr Fabian Proft @ProftDr present CONSUL open label RCT of effect of adding NSAIDS to TNFi on structural outcomes. Bottom line, no significant difference in mSASSS. However new syndesmophytes in 11% vs 25%. @RheumNow #EULAR2022 OP0018 https://t.co/OcYH6oKbJQ https://t.co/kxH5vUdibe

Links:

Richard Conway RichardPAConway ( View Tweet)
178,000 cells from knee synovium studied to eval diff in RA vs PsA transcriptomes. With RA: 👉synov Tcells ⬆️TGFB1 express'n 👉⬆️FAP+ THY1+ synovial fibroblasts 👉receptor ligand network➡️synovial T cell & macrophage synergy 👉IL-1b & TGFb synergy #EULAR2022 OP0067 @rheumnow https://t.co/0uaFyqZqBg
TheDaoIndex KDAO2011 ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2022 Annual meeting is sponsored in part by Bristol-Myers Squibb. All content is chosen by RheumNow & its Faculty.

Dr. John Cush RheumNow ( View Tweet)

#Plenary OP0066. Consider Whipple Dz in pts inflammatory rheum dz Screen with PCR saliva/stool samples, confirm with duodenal bx or PCR on joint fluid. pts on doxycycline and HCQ can lead to rapid remission. @rheumnow https://t.co/VcGp8pr3dT
TheDaoIndex KDAO2011 ( View Tweet)
NORD-STAR substudy looking at anticoagulant effects. Important as RA assoc. ⬆️DVT/PE. DMARDs improve haemostatic imbalance, with bDMARDs stronger effect than csDMARD (may relate to better disease control with this) @RheumNow #EULAR2022 OP0059 https://t.co/TKwAZMOZjY https://t.co/IazrfD7z7k

Links:

Richard Conway RichardPAConway ( View Tweet)
#POS0186 #EULAR2022 AURORA2 (Extension of original RCT to 2 years) showed: 💠#lupus nephritis patients on voclosporin maintained meaningful low uPCR and stability of eGFR at 2yrs 💠No unexpected safety signals @RheumNow https://t.co/lnohgW7BsK
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Rahman et al. Factors associated with fatigue and its improvement in trials IL23i guselkumab. Disease activity/function (34%), joints (16%), skin (12%) but 38.5% of fatigue variability remains unexplained. @RheumNow #EULAR2022 OP0025 https://t.co/C08R0IWM3S https://t.co/QnCvPwEwKS

Links:

Richard Conway RichardPAConway ( View Tweet)
Pedersen et al report 6-fold mortality⬆️over 10 years in RA patients with co-existent depression. Even stronger effect in younger patients (<55) @RheumNow #EULAR2022 OP0067 https://t.co/vYYTmTnstQ https://t.co/xKgMu7zaOA

Links:

Richard Conway RichardPAConway ( View Tweet)
NORD-STAR TRIAL drug does better in ttmt naive eRA? 48wks CDAI remission ▶️ w/ ABA and CERTO PEG vs. MTX+ GCs while TCZ not stat ▶️. Is the difference clinically sufficient to recommend these in first intention over MTX ? not convinced 🧐 OP0058 #EULAR22 @rheumnow

Aurelie Najm AurelieRheumo ( View Tweet)

#EULAR OP0067 Incident depression is critical RA co-morbidity! 🚨>6x risk of death in 10 year follow-up🚨 Depression defined as 1st filling of anti-depressants ▶️Bias likely contributes, esp including neuropathic medications such as duloxetine, but data is staggering @RheumNow https://t.co/xpQPDLonLj
Eric Dein ericdeinmd ( View Tweet)
Screen for depression in RA patients! From the #DANBIO registry of 11,000 pts, they found 6X ⬆️mortality in pts w/#RA and #depression . The mortality curve separates early. #Plenary OP0067 @rheumnow #EULAR2022 https://t.co/qfjyejGVzQ
TheDaoIndex KDAO2011 ( View Tweet)
Damien et al on Whipple's Disease presenting as RMD. 73 cases (wow!) Treat Whipples, 93% remission, 94% off DMARD @RheumNow #EULAR2022 OP0066 https://t.co/XQnQq4RNcq

Links:

Richard Conway RichardPAConway ( View Tweet)

#EULAR2022 POS0241 shows JAKi ⬇️ pain catastrophization/central sensitization in RA patient via CSI (Central Sensitization Inventory) and (PCS) Pain Catastrophizing Scale. No decrease of articular inflammation on ultrasound with JAKi shown, but study had just 22 pts @RheumNow

Eric Dein ericdeinmd ( View Tweet)

Bimekizumab (dual IL-17F and IL-17A inhibitor) phase 3 study for treatment of active ankylosing spondylitis demonstrated ASAS40 improvement at wk 14 (44% vs. 25%). #EULAR2022 @RheumNow #ABSTOP0019 https://t.co/eohvNFG3GS
Robert B Chao, MD doctorRBC ( View Tweet)
Sustained benefits #voclosporin in #LupusNephritis AURORA2 - 2 year study POS0186: 👉no unexpected AEs; rate of AEs⬇️over time 👉COVID19 seen in 12 controls, 7 VCS 👉4 deaths w/control arm vs 0 deaths w/ VCS 👉GFR & sCr & reduction in UPCR remained stable #EULAR2022 @rheumnow

TheDaoIndex KDAO2011 ( View Tweet)

×